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Background. Human immunodeficiency virus (HIV)-infected adults, particularly those of black race, are at
high-risk for end-stage renal disease (ESRD), but contributing factors are evolving. We hypothesized that improve-
ments in HIV treatment have led to declines in risk of ESRD, particularly among HIV-infected blacks.
Methods. Using data from the North American AIDS Cohort Collaboration for Research and Design from
January 2000 to December 2009, we validated 286 incident ESRD cases using abstracted medical evidence of dialysis
(lasting >6 months) or renal transplant. A total of 38 354 HIV-infected adults aged 18–80 years contributed 159 825
person-years (PYs). Age- and sex-standardized incidence ratios (SIRs) were estimated by race. Poisson regression was
used to identify predictors of ESRD.
Results. HIV-infected ESRD cases were more likely to be of black race, have diabetes mellitus or hypertension,
inject drugs, and/or have a prior AIDS-defining illness. The overall SIR was 3.2 (95% confidence interval [CI], 2.8–
3.6) but was significantly higher among black patients (4.5 [95% CI, 3.9–5.2]). ESRD incidence declined from 532 to
303 per 100 000 PYs and 138 to 34 per 100 000 PYs over the time period for blacks and nonblacks, respectively,
coincident with notable increases in both the prevalence of viral suppression and the prevalence of ESRD risk factors
including diabetes mellitus, hypertension, and hepatitis C virus coinfection.
Conclusions. The risk of ESRD remains high among HIV-infected individuals in care but is declining with im-
provements in virologic suppression. HIV-infected black persons continue to comprise the majority of cases, as a
result of higher viral loads, comorbidities, and genetic susceptibility.
Keywords. end-stage renal disease (ESRD); chronic kidney disease (CKD); HIV infection/AIDS; HIV/AIDS;
glomerular filtration rate (GFR).
Since the human immunodeficiency virus (HIV) epi-
demic began, several renal complications resulting from
HIV infection of renal cells, immune dysregulation, and
specific medications have been noted among individuals
infected with HIV [1, 2]. The most severe of these, HIV-
associated nephropathy (HIVAN), caused an estimated
35% of kidney lesions among HIV-infected patients biop-
sied during 1995–2004 [3] and was the fourth leading
cause of end-stage renal disease (ESRD) among black in-
dividuals aged 20–64 years in 1994–1998 [4].
The incidence of HIVAN has declined with increased
use of potent antiretroviral therapy (ART) [5–7]; how-
ever, there are other potential causes of ESRD in HIV-
infected persons. Antiretroviral medications have renal
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effects including nephrotoxicity and stone formation [8].
Comorbidities such as diabetes mellitus, hypertension, and
hepatitis C virus (HCV) infection are risk factors for progres-
sion to ESRD and are more common among HIV-infected per-
sons [9–11]. Illicit drug use, which is more common among
HIV-infected populations, also increases the risk of ESRD [12,
13]. Studies suggest that HIV-infected persons are more likely to
experience ESRD than HIV-uninfected persons, with estimated
incidence rates (IRs) in the US and Europe of 3–10 per 1000
person-years [14, 15] and 0.5 per 1000 PYs [16, 17], respectively,
corresponding to a 2- to 20-fold greater risk compared with the
general population.
A large racial discrepancy has been noted in the burden of
ESRD among HIV-infected and -uninfected individuals, with
disproportionately higher risk borne by black individuals [17,
18]. Data from the United States Renal Data System (USRDS)
indicated that the age- and sex-adjusted incidence of ESRD
was approximately 3.4 times higher among blacks in the general
population compared with whites in 2010 [19]. Whether reduc-
tions in the incidence of HIVAN have impacted the magnitude
of the racial disparity in rates of ESRD among HIV-infected in-
dividuals is unknown.
There is sparse information on the evolving face of ESRD in
the HIV-infected population despite the significant burden of
morbidity and mortality that ESRD presents [20–23]. Given
the many potential contributors to ESRD risk, the goal of the
present study was to assess the relative contributions of clinical
and demographic factors to ESRD incidence and describe recent
trends in ESRD risk in a cohort of HIV-infected individuals
who are representative of HIV patients in care [24]. Our data,
which include ESRD cases validated through an extensive med-
ical record review of HIV-infected patients in clinical care
through 2009, allowed us to capture changes in ESRD incidence
concurrent with, and likely reflective of, modern therapy im-
provements. We hypothesized that well-documented improve-
ments in HIV treatment in the modern therapy era have led
to declines in risk of ESRD over this period, particularly
among HIV-infected black individuals in care, given the dimin-
ishing role of HIVAN.
METHODS
Study Sample
The North American AIDS Cohort Collaboration on Research
and Design (NA-ACCORD) is a consortium of clinical and in-
terval HIV cohorts from Canada and the United States [25]. It
is one of 7 regional collaborations of the International Epide-
miologic Databases to Evaluate AIDS supported by the
National Institutes of Health and draws participants from
>100 clinical sites to represent HIV-infected persons engaged
in clinical care. In brief, each contributing cohort uses
standardized cohort-specific methods of data collection. At
scheduled intervals, cohorts securely transfer demographic,
medication, laboratory, diagnosis, and vital status information
to the NA-ACCORD central Data Management Core (Univer-
sity of Washington), where data undergo quality control for
completeness and accuracy before they are combined into
harmonized data files. The human subject activities of the
NA-ACCORD and each participating cohort study have been
reviewed and approved by their respective local institutional
review boards and the Johns Hopkins School of Medicine.
Eleven clinic-based cohorts (9 in the United States and 2 in
Canada) within the NA-ACCORD used medical record evi-
dence to validate cases of ESRD.
ESRD Validation
A screening algorithm identified potential ESRD cases as those
subjects who had 2 estimated glomerular filtration rates (eGFRs;
calculated from the Chronic Kidney Disease Epidemiology
Collaboration [CKD-EPI] equation [26]) <30 mL/minute/
1.73 m2 measured >90 days apart with no intervening eGFR
≥30 mL/minute/1.73 m2, or a diagnosis of ESRD, kidney trans-
plant, or dialysis. Each potential case identified between January
2000 and December 2009 underwent validation for ESRD by
review of all available laboratory and clinical records for medi-
cal evidence of (1) hemodialysis or peritoneal dialysis; (2) renal
transplant; or (3) arteriovenous fistula (AVF) placement with
additional evidence of dialysis, using a standardized protocol.
Dates of renal transplant, dialysis initiation or AVF placement,
confirmation source, kidney biopsy reports, medication use, and
substance use were all abstracted frommedical records as part of
the validation process and recorded in a centralized Web-based
data entry application. Dialysis delivered temporarily (renal re-
placement therapy lasting <6 months) for acute kidney injury in
hospitalized subjects was not considered ESRD. ESRD date was
defined as the earliest confirmed date of chronic renal replace-
ment therapy or, when not available, the date of AVF placement.
Covariate Definitions
ART was defined as a combination of 3 antiretroviral agents
from at least 2 classes or a triple nucleoside/nucleotide reverse
transcriptase inhibitor regimen containing abacavir or tenofovir.
Self-reported race was categorized as black, white, or other/
unknown, and ethnicity was categorized as Hispanic or non-
Hispanic. For most analyses, the race/ethnicity categories were
collapsed to black and nonblack. CD4+ cell count was catego-
rized as <200, 200–349, 350–499, or ≥500 cells/µL. Plasma
HIV RNA level ≤400 copies/mL was considered suppressed.
For analyses, HIV RNA level was combined with any antiretro-
viral drug (ARV) use to form a 3-category variable: (1) off
ARVs, (2) on ARVs and HIV RNA >400 copies/mL (unsup-
pressed), or (3) on ARVs and HIV RNA ≤400 copies/mL
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(suppressed). History of AIDS-defining illness was based on
clinical diagnoses. History of injection drug use (IDU) was
based on self-report of HIV transmission risk factors. Hyper-
tension was defined as the use of antihypertensive medica-
tion, diagnosis of hypertension, ≥2 systolic blood pressure
readings >140 mm Hg, or ≥2 diastolic blood pressure readings
>100 mm Hg. Diabetes was defined as the use of insulin or oral
hypoglycemic medication, diagnosis of diabetes, fasting blood
glucose >200 mg/dL, or glycosylated hemoglobin >6.5%.
HCV-positive serostatus was defined based on a reactive HCV
antibody or detectable HCV RNA level. The Kidney Disease:
Improving Global Outcomes (KDIGO) classifications based
on eGFR thresholds were used to define eGFR categories repre-
senting severity of chronic kidney disease (CKD) [27].
Statistical Analysis
Person-time accrued from study enrollment on or after 1 Janu-
ary 2000 to the end of the study period on 31 December 2009,
death, ESRD, or 1 year after the last serum creatinine measure-
ment. Age- and sex-standardized (directly standardized) IRs
were calculated overall and by calendar year using the Centers
for Disease Control and Prevention’s Bridged Race Intercensal
Estimates Dataset, which uses year 2000 census data [28]. Con-
sistent with USRDS methods [19], a 3-year rolling average was
used to present a smoothed trend over calendar time. Trends in
comorbidity prevalence were also estimated using the propor-
tion of participants with any past occurrence of hypertension,
diabetes, or HCV infection according to the aforementioned
definitions. The trend in viral suppression was estimated using
the proportion in a given year with all reported viral load mea-
surements ≤400 copies/mL. Age-, sex-, and race-standardized
(indirectly standardized) sex-standardized incidence ratios (SIRs)
were estimated using rates from the USRDS [19]. To avoid possi-
ble bias resulting from higher prevalence of IDU among the
NA-ACCORD HIV-infected participants, only the subset of
cases without reported IDU were used in the SIR analysis.
Adjusted incidence rate ratios (IRRs) and 95% confidence in-
tervals (CIs) were estimated using multivariate Poisson regres-
sion models that included the following covariates: age, CD4+
count, HIV RNA, and ARV use as time-varying; female sex,
black race, IDU, AIDS, hypertension, diabetes mellitus, and
HCV seropositivity as time-fixed using the measurement closest
to entry into the present study (within 6 months).
Lastly, to assess the predictors and correlates of ESRD in vi-
rally-suppressed participants, a separate analysis looked at the
incidence of ESRD among the subset of well-suppressed indi-
viduals. A well-suppressed individual was defined as one whose
HIV RNA measurements were ≤400 copies/mL for 90% of the
observed follow-up time.




The screening algorithm identified 822 potential cases of ESRD.
Of these, 616 were validated as having ESRD for a positive pre-
dictive value of 75%, with only 4 of the 822 not validated due to
missing medical records. After removing 15 cases with missing
year of diagnosis and 9 cases where AVF placement was the only
evidence of ESRD, there were 592 cases. Of these cases, 286 were
incident ESRD cases used in the analysis (Supplementary Ap-
pendix Figure A1). In 62 (22%) of these, a missing month
and/or day of ESRD was imputed as January and/or the 1st, re-
spectively. Date of AVF placement was used in 44 (15%) cases,
in which the start date of dialysis was unknown.
Characteristics of HIV-Infected Adults With ESRD
A total of 38 354 HIV-infected adults aged 18–80 years contrib-
uted 159 825 PYs to this analysis. A cohort-level description of
ESRD cases and PYs contributed is provided in the Supplemen-
tary Appendix. The median follow-up time was 3.6 years (inter-
quartile range [IQR], 1.6–6 years). At study entry, HIV-infected
participants had a median age of 41 years (IQR, 34–47 years).
HIV-infected adults who later developed ESRD were more like-
ly to be female and of black race, have a history of diabetes, hy-
pertension, IDU, or AIDS-defining illnesses, and have an
unsuppressed HIV RNA load while on any ARVs, compared
with participants who did not experience ESRD during the pe-
riod of observation (Table 1). The median baseline CD4+ cell
counts were 236 and 346 cells/µL in ESRD cases and noncases,
respectively. The proportion prescribed ART at study entry was
57% in ESRD cases and 49% in noncases, and no differences
were seen in use of tenofovir, atazanavir, or boosted protease in-
hibitor regimens (Table 1).
Comparison of HIV-Infected ESRD Cases With the General
Population
Using USRDS data as reference, the overall SIR contrasting the
expected number of ESRD cases in HIV-infected non-IDU par-
ticipants by age-, race-, and sex-specific strata to the observed
was 3.2 (95% CI, 2.8–3.6). When stratified by race/ethnicity,
the SIR was 4.5 (95% CI, 3.9–5.2) for blacks, 1.5 (95% CI,
1.0–2.2) for whites, and 1.7 (95% CI, 1.1–2.5) for Hispanics,
compared with race/ethnicity-specific USRDS reference data.
By calendar period, the overall SIR was 3.9 (95% CI, 3.3–4.6)
in 2000–2004 and 2.8 (95% CI, 2.4–3.3) in 2005–2009.
Trends in ESRD Rates and Risk Factors Over Time
Figure 1 shows the age- and sex-standardized incidences over
time in the NA-ACCORD sample, using a 3-year moving aver-
age to smooth the trend (eg, the reported incidence in 2001
is the average of the standardized incidence estimated from
2000 to 2002). We also present the age- and sex-standardized
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incidence over time in the general population as reported in the
2013 USRDS annual report [19]. Overall, HIV-infected partic-
ipants experienced higher rates of ESRD compared with the ge-
neral population across all calendar years, with evidence of a
declining temporal trend (from 317 to 119 per 100 000 PYs
in 2001 and 2008, respectively, Ptrend < .001), coincident with
overall improvements in median CD4+ cell count and viral
suppression. When stratified by race/ethnicity, the increased
ESRD rate noted overall was largely driven by very high rates
in HIV-infected black individuals, though there was evidence
of a decline in ESRD incidence over calendar time among
HIV-infected black patients. The ESRD incidence appeared to
decline annually by 28 per 100 000 PYs per year (95% CI,
−40 to −16) in black individuals from a high of 532 per
Table 1. Baseline Characteristics for HIV-Infected Study Participants With a Comparison to End-Stage Renal Disease Cases Reported in the





(N = 38 068)
ESRD Cases in the
Population Data From
2000–2009 USRDS [19]b
Male sex, % 69 80 55
Race, %
White 11 43 64
Black 80 32 30
Hispanic ethnicity, % 6 13 13
Age, y 43 (36–49) 40 (34–47) 63
Body mass index, kg/m2 25 (22–29) 25 (22–28) 28
Diabetes, % 20 4 47
Hypertension, % 50 17 25
Hepatitis C, % 11 5







Follow-up time, y 2.9 (1.1–5) 3.6 (1.6–6)
HIV-related factors
CD4+ count, cells/µL 236 (118–432) 346 (178–536)
Viral load, copies/mL 13 262 (405–66 417) 3244 (<400–46 171)
On ART 57 49
ARV/viremia status, %
On ARV, suppressed 18 27
On ARV, unsuppressed 36 20
Off ARV 35 43
AIDS 35 21
Injection drug use, % 19 13
History of tenofovir use, % 2.8 5.2
History of atazanavir use, % 1.4 2.6
History of boosted PI use, % 13.6 11.3
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral drugs; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HIV, human
immunodeficiency virus; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; PI, protease inhibitor; USRDS, US Renal Disease
System.
a Statistically significant differences were assessed P < .05 by χ2 test or Wilcoxon rank-sum test comparing ESRD cases in NA-ACCORD with noncases in NA-
ACCORD. All factors but body mass index, tenofovir use, atazanavir use, boosted PI use, and follow-up time (not tested) were significantly different.
b Comorbidity prevalence based on primary diagnosis; mean age from 2011 incident cases.
c Calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [26]; GFR divided into categories based on the Kidney Disease:
Improving Global Outcomes chronic kidney disease stages [27].
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100 000 PYs, and by 16 per 100 000 PYs per year (95% CI, −19
to −13) in nonblack patients from a high of 138 per 100 000
PYs.
The decline in ESRD incidence contrasted with an increase in
the prevalence of comorbidities that are known risk factors for
ESRD (Figure 1; Table 2). ESRD cases in both black and
nonblack patients diagnosed from 2005 to 2009 were more like-
ly to have a history of hypertension compared with cases diag-
nosed from 2000 to 2004 (P = .018 and P = .030, respectively).
Among ESRD cases in black patients, there was a higher prev-
alence of HCV infection in the later calendar period (P = .03).
Among nonblack ESRD cases, there was a nonsignificant
Figure 1. Age- and sex-standardized incidence of end-stage renal disease among human immunodeficiency virus (HIV)-infected adults stratified by race
and compared with age- and sex-standardized rates in the general population (US Renal Database System). Incidence rates are 3-year rolling averages.
Abbreviation: PY, person-years.
Table 2. Characteristics of Cases at the Time of Diagnosis (±6 Months) by Calendar Period
Characteristic
Early ESRD 2000–2004 (n = 145) Late ESRD 2005–2009 (n = 141)
Overall Black (n = 114) Nonblack (n = 31) Overall Black (n= 115) Nonblack (n = 26)
Male sex, % 67 63 81 71 69 81
Age, y 44 (38–51) 44 (38–50) 47 (39–56) 47 (41–54) 47 (42–54) 49 (40–61)
Diabetes, % 25 25 26 28 26 39
Hypertension, % 68 70 58 84 84 85
Hepatitis C, % 10 11 10 18 21 8
HIV-related factors
CD4+ count, cells/µL 176 (36–320) 176 (26–344) 177 (107–264) 246 (118–448) 248 (112–448) 229 (138–457)
Viral load, copies/mL 6093 (400–70 104) 8009 (400–85 557) 637 (<400–21 083) 400 (<400–28 224) 789 (<400–34 428) <400 (<400–400)
ARV/viremia status, %
On ARV, suppressed 31 26 48 47 41 73
On ARV, unsuppressed 53 56 42 35 40 15
Off ARV 12 12 10 12 13 8
AIDS, % 57 61 45 42 43 39
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ARV, antiretroviral drugs; ESRD, end-stage renal disease; HIV, human immunodeficiency virus.
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increase in the prevalence of diabetes (P = .30). One marked dif-
ference between ESRD cases in black and nonblack patients was
the rate of viral suppression while on ART (Table 2). Twenty-six
percent and 41% of black patients with ESRD were treated with
ARVs and suppressed in the early and later calendar periods,
respectively, vs 48% and 73% of nonblack patients with ESRD
(P = .02 and P = .003, respectively) (Table 2). The striking trend
in improved viral load suppression aligned with the noted de-
cline in ESRD incidence in both black and nonblack patients.
Risk Factors for ESRD Among HIV-Infected Persons
A higher incidence of ESRD was observed among HIV-infected
adults of black race (vs white), of female sex, of older age, with a
history of IDU, and in lower baseline eGFR category (Table 3).
Within the subset who maintained suppressed HIV RNA loads
(n = 22 cases occurring over 32 222 PYs), risk factors remained
consistent, but absolute rates of ESRD were much lower (68 per
100 000 PYs overall) and approached that seen in the general
population (35 per 100 000 PYs) [19].
Figure 2 shows the results of the unadjusted and adjusted
Poisson regression. The adjusted IRRs were significantly higher
for black patients, those with unsuppressed viral loads while on
ARVs, those with lower CD4+ counts, and those with a history
of AIDS. Three well-established risk factors for ESRD in the ge-
neral population—diabetes mellitus, hypertension, and HCV
infection—were also highly related to the risk of ESRD. As ex-
pected, eGFR category at baseline was strongly associated with
the risk of ESRD, with adjusted IRRs that increased stepwise
from 3.2 to 48 with increasing CKD severity, compared to par-
ticipants with eGFR >90 mL/minute/1.73 m2. Older HIV-
infected persons were at higher risk of ESRD in unadjusted
analyses; however, with adjustment for comorbidities and base-
line kidney function, that trend reversed, consistent with selec-
tive survival of healthier individuals, such that for any given
Table 3. Unadjusted Incidence Rates of End-Stage Renal
Disease Among HIV-Infected Patients in Care
Characteristic
Incidence Rate per 100 000 PY (95% CI)
Overall (N = 286) Well-Suppresseda (n = 22)
Overall 179 (160–201) 68 (45–104)
Sex
Male 157 (136–180) 56 (34–93)
Female 259 (211–320) 127 (61–269)
Race
White 45 (32–64) 13 (3–51)
Black 437 (384–498) 204 (121–345)
Ethnicity
Hispanic 80 (49–130) 65 (21–202)
Risk behavior
IDU 263 (202–343) 161 (60–428)
Non-IDU 166 (146–189) 61 (38–96)
Age, y
18–39 142 (114–177) 45 (17–120)
40–49 172 (143–206) 52 (25–109)
50–59 234 (185–295) 83 (37–184)
≥60 285 (190–429) 195 (81–469)
eGFR category, mL/min
≥90 73 (57–93) 11 (3–42)
60–89 233 (176–308) 51 (17–159)
45–59 1875 (1340–2625) 772 (290–2056)
30–44 4778 (3396–6720) 2008 (647–6225)
15–29 14 674 (10 197–21 117) 3193 (449–22 668)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration
rate; HIV, human immunodeficiency virus; IDU, injection drug use; PY,
person-years [26].
a Defined as HIV RNA ≤400 copies/mL for 90% of the observed follow-up
time.
Figure 2. Unadjusted and adjusted incidence rate ratios for end-stage
renal disease (ESRD) risk factors. Adjusted estimates are from multivariate
Poisson models adjusting for all factors presented. All factors were as-
sessed at baseline except for age, CD4+ count, human immunodeficiency
virus (HIV) RNA, and antiretroviral drugs (ARV) use, which were a time-
varying factors. Age is shown in years. Abbreviations: CI, confidence
interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration
rate (mL/min) [26]; HCV, hepatitis C virus; HTN, hypertension; IDU, injection
drug use; VL, viral load (copies/mL).
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level of baseline kidney dysfunction, older age represents a bet-
ter risk profile and slower CKD progression. Estimates are also
presented in Supplementary Appendix Table A2.
DISCUSSION
Over the past decade, HIV care has dramatically improved, as
evidenced by increasing rates of viral suppression and declining
numbers of new AIDS diagnoses and deaths in the United
States and Canada [24, 29, 30]. Whereas rates of HIVAN—
which is directly linked to HIV viremia among black individuals
[31]—have fallen since their peak in the pre-ART era [5–7],
HIV-infected blacks in care remain at high risk for ESRD. In
this large collaborative cohort of HIV-infected persons in
care, we observed that ESRD risk was approximately 6 times
higher in black HIV-infected adults compared to their white
counterparts, a disparity in risk that remained after accounting
for sex, IDU, HIV severity, ART use, baseline eGFR, comorbid-
ity history, and age differences. Although ESRD IRs are declin-
ing in the HIV-infected population coincident with overall
improvements in viral suppression, HIV-infected black patients
with incident ESRD in our study continue to exhibit higher viral
loads than their nonblack counterparts. This may result from
previously reported lower ART utilization and delayed entry
into care seen among HIV-infected black patients [32]; differen-
tial access to care is unlikely to underlie our observations, as all
NA-ACCORD participants are engaged in clinical care. Unsup-
pressed viral load and prior AIDS diagnoses were important risk
factors for ESRD in our study, which is consistent with some but
not all prior studies [14–16, 23]. Thus, further reductions in
ESRD risk among HIV-infected blacks may be attained by elim-
inating racial differences in treatment while in care.
Racial disparities in the risk of ESRD would likely persist even
given similar rates of viral suppression as a result of genetic sus-
ceptibility to more aggressive CKD progression through APOL1
risk variants [33, 34]. Innate immune activation leads to poten-
tially damaging overexpression of APOL1 protein among carri-
ers of APOL1 high-risk alleles, who are almost exclusively black
and comprise 13% of the US black population [35, 36]. Thus,
HIV-associated immune activation, which continues even
after immune restoration and viral suppression [37], may dis-
proportionately increase ESRD risk among HIV-infected
black individuals carrying APOL1 risk alleles. Such a mecha-
nism could explain the elevated risk noted in well-suppressed
HIV-infected black patients in NA-ACCORD and would sug-
gest that earlier entry into care, earlier ART initiation, and
long-term viral suppression to attenuate immune activation
may be particularly important for renal protection in blacks.
Immune activation is an important ESRD risk factor, even in
HIV-infected individuals who do not carry APOL1 risk vari-
ants, through its impact on age-related comorbidity risk [37].
Kidney disease resulting from comorbid risk factors may be
supplanting that caused by HIV; trends in comorbidity preva-
lence demonstrate the increasing presence of hypertension, di-
abetes mellitus, and HCV infection among our cohort. Diabetes
and hypertension have been previously found to be strong pre-
dictors of ESRD risk in HIV-infected adults [14].A recent study
by Ryom et al found effect estimates similar to the present study
[23]. Lower CD4+ counts and higher viral loads characterized
early ESRD cases, whereas those occurring after 2005 were
less advanced in their HIV disease but had more comorbidity.
Prevention and treatment of comorbidities in HIV-infected
populations may be the future of ESRD prevention in the mod-
ern ART era.
This study describing ESRD trends and risk factors was
strengthened by the extensive follow-up of a large population
of HIV-infected individuals from >100 clinical sites across
North America. It should be noted this breadth of representa-
tion also results in heterogeneity in terms of individual cohort
ESRD risk, as shown in the Supplementary Appendix Table A1
where cohort IR estimates range from 0 to 550 per 100 000 PYs.
The rigorous validation process for ESRD diagnoses assured
high specificity of the case definition. GFR was estimated using
the CKD-EPI equation, a serum creatinine–based estimating for-
mula, which has been recently validated in an HIV-infected pop-
ulation [38]. The study is limited, however, in the degree to which
we can explore myriad potential contributing factors such as
smoking, recreational drug use, and non-ARV nephrotoxic med-
ication use as well as kidney disease biomarkers such as urine
protein, as these data were not consistently collected across the
cohorts at the time of the ESRD validation. Socioeconomic fac-
tors that may drive discrepancies in viral load suppression rates
between blacks and nonblack patients were not collected.
In conclusion, our findings suggest that HIV-infected indi-
viduals have benefited from improved viral suppression in
terms of ESRD risk, despite an apparent rising trend in the
prevalence of comorbid risk factors for kidney disease. How-
ever, there remains a large racial disparity in ESRD risk resulting
from several potential mechanisms: (1) continued disparities in
ARV use and viral suppression; (2) higher rates of comorbid
risk factors for kidney disease; and (3) differences in genetic or
gene–environment risk profiles. These racial differences in
ESRD risk have important implications. They highlight the
need for continued efforts to close racial gaps in early access to
ART to achieve durable viral suppression as well as early inter-
ventional strategies for comorbid risk factors to slow kidney dis-
ease progression in HIV-infected black individuals.
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Health HIV Cohort: Stephen Boswell, Chris Grasso, and Ken
Mayer; HAART Observational Medical Evaluation and Re-
search: Robert S. Hogg, Richard Harrigan, Julio Montaner,
and Angela Cescon; HIV Outpatient Study: John T. Brooks
and Kate Buchacz; HIV Research Network: Kelly A. Gebo and
Richard D. Moore; Johns Hopkins HIV Clinical Cohort: Rich-
ard D. Moore; John T. Carey Special Immunology Unit Patient
Care and Research Database, Case Western Reserve University:
Benigno Rodriguez; Kaiser Permanente Mid-Atlantic States:
Michael A. Horberg; Kaiser Permanente Northern California:
Michael J. Silverberg; Longitudinal Study of Ocular Complica-
tions of AIDS: Jennifer E. Thorne; Multicenter Hemophilia
Cohort Study–II: James J. Goedert; Multicenter AIDS Cohort
Study: Lisa P. Jacobson; Montreal Chest Institute Immunodefi-
ciency Service Cohort: Marina B. Klein.
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B. Rourke, Ann Burchell, and Anita R. Rachlis; Retrovirus Re-
search Center, Puerto Rico: Robert F. Hunter-Mellado and
Angel M. Mayor; Southern Alberta Clinic Cohort: M. John
Gill; Studies of the Consequences of the Protease Inhibitor
Era: Steven G. Deeks and Jeffrey N. Martin; University of
Alabama at Birmingham 1917 Clinic Cohort: Michael S. Saag,
Michael J. Mugavero, and James Willig; University of North
Carolina, Chapel Hill, HIV Clinic Cohort: Joseph J. Eron and
Sonia Napravnik; University of Washington HIV Cohort:
Mari M. Kitahata and Heidi M. Crane; Veterans Aging Cohort
Study: Amy C. Justice, Robert Dubrow, and David Fiellin; Van-
derbilt-Meharry Centers for AIDS Research Cohort: Timothy
R. Sterling, David Haas, Sally Bebawy, and Megan Turner;
Women’s Interagency HIV Study: Stephen J. Gange and
Kathryn Anastos.
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Michael S. Saag, Stephen J. Gange, Keri N. Althoff, Mari
M. Kitahata, Rosemary G. McKaig, Amy C. Justice, and
Aimee M. Freeman.
NA-ACCORD Administrative Core: Richard D. Moore,
Aimee M. Freeman, and Carol Lent.
NA-ACCORD Data Management Core: Mari M. Kitahata,
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Morton, and Brenda Simon.
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